Article

ForbesForbes on 2021-07-16 11:00

FibroGen Stock Craters After Roxadustat Setback, But There Is A Silver Lining

Yesterday, the U.S. FDA voted not to approve Roxadustat for the treatment of anemia due to chronic kidney disease in adult patients.

Related news